On November 16, 2022, Illumina, Inc. (NASDAQ: ILMN) and Genetic Alliance announced the creation of the iHope™ Genetic Health program, a $120 million global initiative aimed at providing whole-genome sequencing (WGS) access to tens of thousands of patients across the globe impacted by genetic disease. At least half of iHope Genetic Health's efforts will be focused on areas of the world in need outside the US, with more than one-third of Illumina's support being dedicated to patients in Africa. "By establishing iHope™ Genetic Health, we are expanding our commitment to ensure that the benefits derived from whole-genome sequencing are available to as many people as possible, as quickly as possible, regardless of disease, geography, or income," said Francis deSouza, MS, President and Chief Executive Officer at Illumina. "By unlocking the power of the human genome, we can find answers for these patients where no others can, and dramatically change lives."